NDAINJECTIONINJECTABLE
Approved
Jan 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tubocurarine chloride is a non-depolarizing neuromuscular blocking agent administered by injection used as an adjunct to anesthesia to facilitate intubation and surgical relaxation. It works by competitively blocking acetylcholine at the neuromuscular junction, preventing muscle contraction. This is a legacy product approved in 1947 with historical significance in anesthetic practice.
LOE Approaching
This product faces imminent loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting brand team focused on defending market share against newer agents.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on tubocurarine chloride offers limited career advancement given zero linked job openings and approaching loss of exclusivity. Roles are primarily defensive, focused on protecting installed base and managing decline rather than driving growth or innovation.
Brand ManagerAccount Manager
Worked on TUBOCURARINE CHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.